Who owns gabapentin now in usa?

Who holds gabapentin’s main U.S. rights today (brand vs. generics)?

Gabapentin is an older medicine and is widely available as generic tablets/capsules in the U.S., so “ownership” depends on what product you mean: branded (original or branded generics) versus the many generic manufacturers currently marketing it.

For the brand-side:
- Pfizer originally developed the drug and marketed Neurontin.
- Today, Pfizer is generally associated with Neurontin’s former brand ownership, while generic manufacturers market non-branded gabapentin products.

For the generic-side:
- No single company “owns” all U.S. gabapentin sales in the way a patent holder might. Multiple generic companies can sell gabapentin because generic competition is allowed once relevant exclusivities and patents have expired. As a result, many firms “own” the right to market their specific gabapentin product under FDA approval (ANDA), even though they all use the same active ingredient.

What “ownership” usually means for gabapentin in practice

People asking this often mean one of these:
- Patent holder(s): who controlled legal protection for gabapentin at a given time (largely expired for gabapentin itself).
- Brand holder: who markets the original brand name (Neurontin).
- Market authorization holder: which company currently distributes a particular generic gabapentin product (there are many).

Because gabapentin is now off-patent, today’s market is dominated by generic products sold by different companies, not one owner of the drug ingredient.

If you tell me the product name, I can pinpoint who markets it

If you share the exact label you’re looking at (for example, “Neurontin,” “gabapentin 300 mg,” or an extended-release version like “Horizant”), I can narrow down which company owns/markets that specific product in the U.S. market.

Source

• DrugPatentWatch (gabapentin listings and history): https://www.drugpatentwatch.com/